Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987222 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL29435121 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL29089525 | 0.88 | TARS1 (0.39) | TARS1SLC29A1ADORA1 | |
| SCHEMBL28475028 | 0.87 | SLC29A1 (0.46) | SLC29A1ADORA1LMNATP53ALOX15 | |
| SCHEMBL26090156 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL29413061 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL28300819 | 0.85 | ADORA3 (0.35) | TARS1ADORA1 | |
| SCHEMBL30950292 | 0.85 | TARS1 (0.37) | TARS1SLC29A1ADORA1 | |
| SCHEMBL31675871 | 0.84 | AHCY (0.41) | ADORA1 | |
| SCHEMBL17627818 | 0.84 | RXFP1 (0.39) | SLC29A1ADORA1LMNATP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736871-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-120129688-A | Efficient method for preparing highly purified 5' -capped oligonucleotides | 垂林克生物技术有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-113423418-B | Treatment of cilia disease | 埃泽瑞斯公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-112805386-B | Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail | 埃泽瑞斯公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-117729930-A | Use of IFN-lambda mRNA for the treatment of viral infections | 埃泽瑞斯公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117355329-A | VLP enterovirus vaccine | 摩登纳特斯有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116685682-A | Guided editing guide RNAs, compositions thereof, and methods of using the same | 布罗德研究所股份有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116096873-A | Methods and compositions for editing two strands of a target double-stranded nucleotide sequence simultaneously | 布罗德研究所股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-112805386-A | Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail | 埃泽瑞斯公司 | 2021-05-14 | — | — | CN | disclosed |